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Bacterial infections after lung transplantation cause
airway epithelial injury and are associated with an
increased risk of developing bronchiolitis obliterans
syndrome. The damaged epithelium is a source of
alarmins that activate the innate immune system,
yet their ability to activate fibroblasts in the develop-
ment of bronchiolitis obliterans syndrome has not
been evaluated. Two epithelial alarmins were mea-
sured longitudinally in bronchoalveolar lavages from
lung transplant recipients who developed bronchioli-
tis obliterans syndrome and were compared to
stable controls. In addition, conditioned media from
human airway epithelial cells infected with Pseu-
domonas aeruginosa was applied to lung fibroblasts
and inflammatory responses were determined. Inter-
leukin-1 alpha (IL-1a) was increased in bronchoalveo-
lar lavage of lung transplant recipients growing P.
aeruginosa (11.5 [5.4–21.8] vs. 2.8 [0.9–9.4] pg/mL,
p < 0.01) and was significantly elevated within
3 months of developing bronchiolitis obliterans syn-
drome (8.3 [1.4–25.1] vs. 3.6 [0.6–17.1] pg/mL,
p < 0.01), whereas high mobility group protein B1
remained unchanged. IL-1a positively correlated with
elevated bronchoalveolar lavage IL-8 levels
(r2 = 0.6095, p < 0.0001) and neutrophil percentage
(r2 = 0.25, p = 0.01). Conditioned media from P.
aeruginosa infected epithelial cells induced a potent
pro-inflammatory phenotype in fibroblasts via an
IL-1a/IL-1R-dependent signaling pathway. In conclu-
sion, we propose that IL-1a may be a novel therapeu-
tic target to limit Pseudomonas associated allograft
injury after lung transplantation.
Abbreviations: BAL, bronchoalveolar lavage; BOS,
bronchiolitis obliterans syndrome; CLAD, chronic
lung allograft dysfunction; DAMPs, damage-
associated molecular patterns; HMGB1, high mobility
group protein B1; IL-1a, interleukin-1 alpha; LDH, lac-
tate dehydrogenase; PLEC, primary human lung
epithelial cells; PLF, primary human lung fibroblasts;
RAS, restrictive allograft syndrome
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Introduction
Chronic lung allograft dysfunction (CLAD) causes signifi-
cant loss of function to the transplanted lung and is the
major factor limiting long-term survival after lung trans-
plant (1). When this process affects the small- and
medium-sized airways resulting in airflow limitation, it is
referred to as bronchiolitis obliterans syndrome (BOS).
Histologically, BOS is characterized by progressive loss
of bronchial epithelium, neutrophil influx, chronic inflam-
mation, and fibroproliferation causing small airway obliter-
ation (1–4). BOS affects approximately 50% of patients
within 5 years of transplantation and accounts for 30%
of deaths occurring within 3 years (5).
BOS is a progressive condition that is often accompanied
by repeated episodic or chronic lower respiratory tract
infection (6–8) and numerous studies have shown that
bacterial infection, specifically the gram-negative organ-
ism Pseudomonas aeruginosa, significantly increase the
risk of developing BOS in posttransplant and nontrans-
plant patients (6,9–14). Chronic P. aeruginosa infection
can lead to persistent inflammation and damage of the
respiratory epithelium (15,16), and damaged epithelial
cells may be a source of danger signals referred to as
alarmins or damage-associated molecular patterns
(DAMPs) (17–19). Alarmins are a diverse class of
molecules serving many important intracellular functions
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including maintaining chromatin structure (high mobility
group protein B1 [HMGB1]), regulating protein folding
(heat shock proteins), or modulating gene expression
(interleukin-1 alpha [IL-1a]) (20,21).
Chronic inflammation and progressive fibroproliferation
are two characteristic features of BOS (22). Until quite
recently, fibroblasts have been regarded as cells whose
role was limited to the restoration of tissue architecture
during physiological wound repair or deposition of various
components of extracellular matrix in pathological repair.
However, emerging evidence suggests that fibroblasts
may also function as important mediators of innate
immune responses and may act to modulate the switch
from acute to chronic inflammation, processes that coex-
ist in fibrosis (23).
IL-1a is a member of the interleukin-1 superfamily, which
consists of 11 cytokines including IL-1b, IL-18, and IL-33.
IL-1a has been shown to be elevated in the lungs of
chronic obstructive pulmonary disease patients (24), and
recent work has identified anti-IL-1a autoantibodies in
the blood of idiopathic pulmonary fibrosis patients (25)
and increased levels of IL-1Ra in lung allograft recipients
who developed BOS (26), suggesting that extracellular
IL-1a may be an undesirable and potentially harmful fac-
tor in fibrotic lung diseases. Immune cells such as mono-
cytes and macrophages actively transcribe and release
IL-1a in response to a range of stimuli including metal
particles (27) and bacterial products such as lipopolysac-
charide (28). In contrast, IL-1a is synthesized and consti-
tutively stored in the cytoplasm of epithelial cells. Recent
studies have revealed that damaged epithelial cells can
trigger a proinflammatory phenotype in lung fibroblasts
through the release of DAMPs, specifically IL-1a (19).
Epithelial damage may be a result of infection with bacte-
ria (29) or virus (30) or may be caused by noninfective
insults such as air pollution (31), oxidative stress (32),
aspiration injury (33), or cigarette smoke (24,34). IL-1b is
also upregulated in chronic inflammatory lung diseases
and may be released from activated macrophages (35).
Although IL-1 family members are known to play a role in
mediating the innate immune responses, the relationship
between IL-1a and other alarmins with P. aeruginosa
infection in the development of BOS after lung transplan-
tation has not been investigated. Therefore, in this study
we investigate the relevance of selected alarmins in BOS
and investigate whether P. aeruginosa induced epithelial
cell damage can drive fibroblast activation and in particular
an inflammatory phenotype in lung fibroblasts.
Materials and Methods
This study was approved by the Newcastle and North Tyneside Local
Regional Ethics Committee (2001/179), and informed written consent
was obtained from all study patients.
Bronchoalveolar lavage
All patients had undergone surveillance bronchoscopic evaluation at
approximately 1, 3, 6, and 12 months posttransplant and at the time BOS
was suspected or diagnosed. A standardized 180 mL bronchoalveolar
lavage (BAL) comprising three sequentially administered and suctioned
60 mL washes of saline was performed from a subsegment of the right
middle or lower lobe or left lower lobe (n = 117 from patients who devel-
oped BOS, n = 91 from patients who remained stable). An aliquot was
sent for microbiological culture including extended testing for bacterial
and fungal pathogens. The remaining sample was filtered and the cellular
fraction was separated by centrifugation. Total and differential cell counts
were performed and the supernatant was stored for analysis.
MSD electrochemiluminescence assay
IL-1a and IL-8 concentrations in BAL were measured using MSD electro-
chemiluminescence detection kits (Meso Scale Discovery, Gaithersburg,
MD).
Cell and bacterial culture
See Data S1 Supplementary Materials and Methods in the Supporting
Information.
Epithelial cell treatments
Live P. aeruginosa or heat-killed P. aeruginosa were added to primary
lung epithelial cells (PLEC) (see Data S1 Supplementary Materials and
Methods for details of isolation and culture conditions) at 104 to 108 cfu/
mL. After 12 h the media (hereafter referred to as conditioned media)
was harvested and filtered (0.2 lm) to remove all bacteria.
Fibroblast treatments
Primary lung fibroblasts (PLF) (see Data S1 Supplementary Materials and
Methods for details of isolation and culture conditions) were treated with
conditioned media from P. aeruginosa challenged PLEC that had been pre-
incubated for 1 h with IL-1a or IL-1b neutralizing antibody (both 4 lg/mL)
(R&D Systems, Minneapolis, MN). To inhibit IL-1R signaling, PLF were pre-
treated for 1 h with IL-1Ra (500 ng/mL) (R&D Systems) after which the cul-
ture media was replaced with conditioned media containing the same dose
of IL-1Ra. After 24 h, media was collected for enzyme-linked immunosor-
bent assay (ELISA) analysis. Cells were harvested into NucleoSpin RNA
lysis buffer (Macherey-Nagel, Duren, Germany) for RNA extraction.
PLF were pretreated with dexamethasone or azithromycin (0.31–5 lM)
for 1 or 24 h, respectively, before addition of recombinant human IL-1a
(100 pg/mL) or conditioned media from PLEC challenged with P. aerugi-
nosa. IL-1a was blocked by pre-incubating the conditioned media for 1 h
with IL-1a (4 lg/mL) neutralizing antibody. After 24 h, media was col-
lected for ELISA analysis.
LDH assay
Lactate dehydrogenase (LDH) release was assessed as a measure of
cellular cytotoxicity using the Pierce LDH Cytotoxicity Assay Kit (Thermo
Scientific, Waltham, MA).
ELISA
IL-1a, IL-1b, IL-6, and IL-8 concentrations in cell culture supernatants were
measured using DuoSet kits (R&D Systems). HMGB1 was measured
with a direct ELISA (see Data S1 Supplementary Materials and Methods).
PCR
RNA extraction was performed using Nucleospin RNA II kit (Macherey-
Nagel). Quantitative reverse transcription polymerase chain reaction
(qPCR) was performed using AffinityScriptTM Multiple Temperature RT kit
(Agilent Technologies, Santa Clara, CA). Relative gene expression was
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measured using SYBR Green JumpStartTM Taq ReadyMixTM (Sigma, St
Louis, MO). Primers for qPCR are listed in Supplementary Table S1.
Immunohistofluorescence
Lung tissue sections (5 lm) were deparaffinized in xylene, rehydrated in
graded alcohol, and antigen retrieval was performed in EDTA (1 mM, pH
8.0) for 10 min in a microwave. Samples were blocked in 1% bovine
serum albumin (BSA) and incubated overnight at 4°C with anti-IL-1a (AF-
200-NA, R&D) or an IgG1 control antibody (both 10 lg/mL, 1% BSA).
Slides were washed and incubated with a fluorescein isothiocyanate–
conjugated anti-goat secondary antibody (F7367, Sigma) for 2 h at room
temperature. Slides were washed and mounted in VectorShield mounting
media containing DAPI (Vector Laboratories, Burlingame, CA). Images
were acquired using a Leica TCS SP2 UV confocal microscope.
Statistical analysis
Mean log10 of IL-1a, IL-8, and HMGB1 concentration and neutrophil num-
ber and percentage in BAL samples per patient were used for analysis.
Additional stratification of patient BAL samples were performed to com-
pare differences in BAL samples collected <3 months before or after
BOS diagnosis versus BAL samples collected >3 months before or after
BOS diagnosis (Figures 2 and S1) and in patients with culture positive
(any organism or P. aeruginosa) compared to culture negative BAL sam-
ples (Figures 3, S2, and S5).
Changes in log10 of IL-1a and HMGB1 concentration and neutrophil num-
ber and percentage in BAL samples collected longitudinally were
assessed using a random-effects model, with patients as the random
component (Figures 2, 3, S1, S3, and S4). All p-values relate to the gradi-
ent of the fitted line. To plot an average line, we took the mean value at
T0 (BOS only–time of BOS diagnosis taken as T0) or T6 (stable only–time
of transplant was taken as T0) as the y-intercept.
Data were analyzed using chi-square test for trend test, paired Student’s
t-test for normally distributed data, or Mann–Whitney U test for non-
normally distributed data as appropriate. Significance was defined by
p < 0.05. Results are presented as median (Figures 2, 3, S1, S2, and S5)
or mean (standard error of the mean) (Figures 4, 5, and 6).
Results
Patient characteristics
Our transplant program performed 210 lung transplants
from 2005 to 2010. Patients were excluded from our ret-
rospective study due to early death (within 3 months of
transplantation) (n = 24) and for development of restric-
tive allograft syndrome (RAS) within 3 years of transplan-
tation (n = 14). Of the remaining patients, n = 25
(13.4%) developed BOS within 3 years of transplanta-
tion. BOS was diagnosed in accordance with Interna-
tional Society for Heart and Lung Transplantation
guidelines (36). All patients demonstrated persistent
obstructive spirometry with an FEV1 of <80% of their
posttransplant baseline. All had acute rejection or active
infection excluded at bronchoscopy as the explanation
for their graft dysfunction and had high-resolution com-
puted tomography lung imaging consistent with BOS
and with no evidence of parenchymal changes of poten-
tial RAS. A nested case-controlled group of n = 25
patients was identified from the n = 147 lung transplant
recipients who remained stable at 3 years posttrans-
plant. The limited size of the whole control cohort meant
it was not possible to individually pair each case with a
control adequately for type of transplant, age, sex, and
number of acute rejection episodes and therefore the
approach adopted was for the control group as a whole
to have an age, sex, and acute rejection history profile
as close as possible to the cases. The controls were ini-
tially identified by closest age to the cases and then gen-
der and finally acute rejection episodes. Controls were
then removed to improve the matching of the overall
control group to the cases until a final n = 25 were iden-
tified (Figure 1 and Table 1).
There was no significant difference in the type or num-
ber of organisms cultured from BAL (Tables 1, S2, S3,
and S4); however, there was a significant difference in
the number of BAL samples per patient, with more
samples collected from the BOS group compared to the
stable group (p < 0.001) (Table 1). This was primarily
due to more symptom-driven bronchoscopies, in addi-
tion to the surveillance bronchoscopies, in the BOS
group.
IL-1a is elevated in BAL of patients with
posttransplant BOS
To evaluate the clinical relevance of alarmins in the trans-
planted lung, IL-1a and HMGB1 concentration and the
percentage and number of neutrophils were measured in
BAL fluid collected longitudinally from n = 25 lung trans-
plant recipients who developed BOS within 3 years of
transplant and a nested case-controlled group of n = 25
patients who remained stable. BAL samples collected
more than 3 months before or after BOS diagnosis
(>3 months before BOS) and BAL samples collected
<3 months before or after BOS diagnosis (<3 months
before BOS) were grouped. HMGB1 was not significantly
different between BAL samples collected more than
3 months before BOS diagnosis and BAL samples col-
lected within 3 months of BOS diagnosis (p = 0.60)
(Figures S1A and B). However, IL-1a was significantly
higher in BAL collected within 3 months of BOS diagno-
sis compared to BAL collected more than 3 months
before BOS diagnosis (p < 0.0001) (Figures 2A and S1A).
Additionally, there was an increase in the percentage and
number (both p < 0.01) of neutrophils in BAL collected
within 3 months of BOS diagnosis compared to BAL col-
lected more than 3 months before BOS diagnosis (Fig-
ures 2B and S1A and C). Moreover, IL-1a concentration
(r2 = 0.48, p = 0.0003) and neutrophil percentage
(r2 = 0.48, p = 0.0056) (Figures 2C and D), but not
HMGB1 concentration (r2 = 0.34, p > 0.99) (Figure S1D),
showed an increase towards the time of BOS diagnosis.
Finally, there was a positive correlation between the per-
centage of neutrophils (r2 = 0.25, p = 0.011) and IL-8
levels (r2 = 0.61, p < 0.0001) (Figures 2E and F) with IL-
1a concentration in BAL of patients who develop BOS.
These observations are in agreement with previous
American Journal of Transplantation 2016; 16: 1751–1765 1753
Pseudomonas Induced Epithelial Injury in CLAD
reports showing the association between neutrophilia
and BOS development (37,38).
IL-1a levels are increased in BAL from patients with
positive organism cultures
We proceeded to investigate IL-1a and HMGB1 levels and
the number and percentage of neutrophils in BAL sam-
ples from BOS and non-BOS patients without organisms
cultured (culture negative) or with any positive organism
culture (culture positive). IL-1a was significantly increased
in culture positive BAL compared to culture negative BAL
(p < 0.05) in patients who develop BOS. In addition, IL-1a
was significantly increased in culture positive BAL from
patients who develop BOS compared to culture positive
BAL from non-BOS patients (p < 0.05). Interestingly, a
non–statistically significant trend towards an increase in
IL-1a concentration in BOS culture negative BAL com-
pared to non-BOS culture negative BAL (p = 0.07) was
seen suggesting that, apart from bacterial or fungal infec-
tion, other factors driving IL-1a release may be implicated
in BOS (Figure 3A). BAL neutrophil percentage and num-
ber (both p < 0.05) were also increased in culture positive
BAL compared to culture negative BAL in BOS patients.
Similar to IL-1a, BAL neutrophil percentage and numbers
were significantly higher in BOS culture positive BAL
compared to non-BOS culture positive BAL (both
p < 0.001) (Figures 3B and S2B). In contrast, no differ-
ence in HMGB1 levels was observed between groups
(Figure S2A).
IL-1a concentrations and neutrophilia in BAL presented as
relative time from BOS diagnosis in culture positive and
culture negative BAL samples demonstrated that there is
a positive correlation between IL-1a and time from BOS
diagnosis in the BOS culture positive group (r2 = 0.38,
p = 0.0016) and a non–statistically significant trend
between IL-1a and time from BOS diagnosis in the BOS
culture negative group (r2 = 0.58, p = 0.10) (Figures 3C
and D). In addition, there was a positive correlation
between neutrophil percentage and time from BOS diag-
nosis in the BOS culture positive group (r2 = 0.41,
p = 0.019) and a non–statistically significant trend
between neutrophil percentage and time from BOS diag-
nosis in the BOS culture negative group (r2 = 0.50,
p = 0.14) (Figure S3). Finally, no correlation was observed
between IL-1a or HMGB1 concentrations and neutrophil
percentage or number relative to the number of months
from transplantation in non-BOS patients (Figure S4).
Figure 1: Patient selection. All lung transplant patients (n = 210) from March 2005 to February 2010 were considered for inclusion
in the retrospective study cohort. n = 24 were excluded due to early death (within 3 months of transplantation) and n = 14 were
excluded for development of restrictive allograft syndrome (RAS) within 3 years of transplantation. Of the remaining patients, n = 25
(13.4%) developed BOS within 3 years of transplantation and were selected as our study population. n = 147 remained free from
BOS at 3 years, and n = 25 were selected as a case-controlled group. The nested case–control group was matched for type of trans-
plant, age, sex, and number of acute rejection episodes. BOS, bronchiolitis obliterans syndrome.
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IL-1a levels are increased in P. aeruginosa positive
BAL samples isolated from patients with
posttransplant BOS
IL-1a and neutrophil percentage were significantly
increased in BAL positive for P. aeruginosa compared to
culture negative BAL (both p < 0.05) in patients who
developed BOS. No significant difference in IL-1a or
neutrophil percentage was seen between BAL positive
for all other organisms and culture negative BAL in
patients who developed BOS (p = 0.14 and p = 0.24,
respectively). In contrast, no significant difference was
seen in IL-1a levels and neutrophil percentage in BAL
positive for P. aeruginosa compared to culture negative
BAL in non-BOS patients (p = 0.41 and p = 0.15,
Table 1: Patient demographics
BOS Non-BOS p-value
Number of patients 25 25
Median age (years) 46 (23–63) 45 (19–64) p = 0.47
Sex distribution
Male 15 20 p = 0.12
Female 10 5
Number of acute rejection episodes 22 21 p = 0.35
Median number of BAL samples per patient 5 (2–8) 3 (2–4) p < 0.001
Underlying condition
BOS Non-BOS
p-valueNumber % Number %
COPD 9 36% 2 8% p = 0.37
Cystic fibrosis 6 24% 11 44%
Fibrotic lung disease 5 20% 8 32%
a1-Anti-trypsin deficiency 2 8% 2 8%
Asthma 1 4% 0 0%
Histiocytosis 1 4% 0 0%
Lymphangioleiomyomatosis 1 4% 0 0%
Primary pulmonary hypertension 0 0% 1 4%
Bronchiectasis 0 0% 1 4%
Type of transplant
BOS Non-BOS
p-valueNumber % Number %
Single lung 9 36% 7 28% p = 0.40
Bilateral lung 16 64% 17 68%
Heart lung 0 0% 1 4%
Organisms cultured from BAL
BOS Non-BOS
p-valueNumber % Number %
Pseudomonas aeruginosa 5 20% 7 28% p = 0.25
Candida albicans 9 36% 11 44%
Aspergillus fumigatus 5 20% 0 0%
Proteus mirabilis 1 4% 0 0%
Stenotrophomonas maltophilia 3 12% 0 0%
Staphylococcus aureus 2 8% 3 12%
Acinetobacter baumannii 1 4% 0 0%
Aspergillus nidulans 1 4% 0 0%
Enterobacter cloacae 1 4% 0 0%
Haemophilus influenzae 1 4% 0 0%
Klebsiella pneumonia 1 4% 0 0%
Serratia spp 1 4% 1 4%
MRSA 0 0% 3 12%
Escherichia coli 0 0% 2 8%
Burkholderia cepacia complex 0 0% 1 4%
Exophiala spp 0 0% 1 4%
No organisms cultured 11 44% 5 20%
BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome; COPD, chronic obstructive pulmonary disease; MRSA,
methicillin-resistant Staphylococcus aureus.
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respectively) (Figures 3E and F). Again, no difference in
HMGB1 was observed (Figure 3G).
BOS and non-BOS patients were divided into those with
no positive BAL cultures, those with one positive BAL cul-
ture, and those with >1 positive BAL culture and IL-1a and
HMGB1 concentration and neutrophil percentage
assessed. BOS patients with more than one positive cul-
ture BAL had significantly higher levels of IL-1a and an
increased percentage of neutrophils than BOS patients
with no positive BAL cultures (both p < 0.05). In contrast,
there was no significant difference in IL-1a concentration
or neutrophil percentage in non-BOS patients (p = 0.053
and p = 0.33, respectively). No difference in HMGB1 was
seen between groups in BOS and non-BOS patients
(Figure S5).
P. aeruginosa infection of epithelial cells in vitro
induced the release of epithelial alarmins including
IL-1a
To evaluate the association between bacterial infection,
IL-1a, neutrophilia, and BOS, we developed an in vitro
A B
C D
E F
Figure 2: Increased neutrophilia and elevated levels of IL-1a in BAL of posttransplant patients at the time of BOS diagnosis.
Mean IL-1a (A) concentrations and neutrophil percentage (B) in BAL of lung transplant recipients who remained stable at 3 years
(n = 25) or develop BOS within 3 years of transplant (n = 25). BALs from patients who developed BOS were grouped into BAL sam-
ples taken more than 3 months before or after BOS diagnosis (>3 months before BOS) and BAL samples taken <3 months before or
after BOS diagnosis (<3 months before BOS). Data were analyzed using Mann–Whitney U test or paired t-tests as appropriate and are
presented as median. Correlation between the relative time from BOS diagnosis and IL-1a concentration (C) and neutrophil percentage
(D) in BAL samples from patients who develop BOS. Data were analyzed using a multiple linear regression model with varying inter-
cept. All p-values relate to the gradient of the fitted line. To plot an average line, we took the mean value at T0 (time of BOS diagno-
sis) as the y-intercept. Correlation is shown between IL-1a concentration and neutrophil percentage (E) and between IL-1a and IL-8
concentrations (F) in BAL samples from patients who develop BOS. Data were analyzed using a linear regression model. **p < 0.01,
***p < 0.001, ****p < 0.0001. BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome.
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F G
Figure 3: IL-1a and neutrophilia are elevated in Pseudomonas aeruginosa positive BAL in patients with BOS. Mean IL-1a
(A) concentration and neutrophil percentage (B) in culture positive (any organism) and culture negative (no organisms) BAL samples
from patients (n = 25) who developed BOS or remained stable (non-BOS) (n = 25). Data were analyzed using Mann–Whitney U test
and are presented as median. Correlation is shown between the relative time from BOS diagnosis and IL-1a concentration in culture
negative (n = 10) (C) and culture positive (n = 15) (D) BAL samples from patients who develop BOS. Data were analyzed using a multi-
ple linear regression model with varying intercept. All p-values relate to the gradient of the fitted line. To plot an average line, we took
the mean value at T0 (time of BOS diagnosis) as the y-intercept. Mean IL-1a concentration (E), neutrophil percentage (F), and HMGB1
concentration (G) in culture negative (no organisms), culture positive for any organism other than P. aeruginosa (other organisms), and
culture positive for P. aeruginosa (P. aeruginosa) BAL samples from patients who remained stable (non-BOS) (i) and patients who
developed BOS (ii). Data were analyzed using Mann–Whitney U test and are presented as median. *p < 0.05, ***p < 0.001. BAL,
bronchoalveolar lavage; BOS, bronchiolitis obliterans syndrome; HMGB1, high mobility group protein B1.
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model of P. aeruginosa infection of the airway epithelium
and its subsequent effects on fibroblast activation. PLEC
were initially infected with a laboratory reference strain
of P. aeruginosa (PA01) at densities ranging from 104 to
108 cfu/mL for up to 24 h, and the release of IL-1a was
quantified. Infection of PLEC with PA01 at 104 and
105 cfu/mL for 12 and 24 h induced cell injury and some
cell death (data not shown) and triggered the release of
IL-1a (Figure 4A). Consequently, a P. aeruginosa density
of 105 cfu/mL was used for all additional experiments.
The effect of PA01 infection on cell viability (data not
shown) and IL-1a release was compared to clinical iso-
lates of P. aeruginosa (n = 7) grown from the airway
samples of posttransplant patients. The ability of the clin-
ical strains to induce IL-1a release was variable; how-
ever, P. aeruginosa strain 4616 (hereafter referred to as
4616) induced the strongest response and was used in
subsequent experiments (Figure 4B). To confirm the suit-
ability of 4616 for our experiments, we infected PLEC
with 105 cfu/mL for up to 48 h and measured cell injury
and death as well as IL-1a release (Figures 4C and D).
Similar to the data generated with PA01, infection of
PLEC with 4616 at 105 cfu/mL induced cell injury, some
cell death, and IL-1a release at 12 h. Subsequent experi-
ments were performed by infecting PLEC with strain
4616 at 105 cfu/mL for 12 h.
PLEC isolated from n = 4 unused donor lungs were cul-
tured for 12 h in media only (media), media containing
heat-killed 4616 (HK4616), or media containing live 4616
at 105 cfu/mL (4616), and the release of epithelial alar-
mins (IL-1a, HMGB1), inflammatory cytokines (IL-1b,
IL-6, IL-8), granulocyte-macrophage colony-stimulating
factor (GM-CSF), and matrix metalloproteinase 3 (MMP3)
measured (Figure 4E). Challenge with live 4616 induced
a significant increase in the release of IL-1a (p < 0.01) (i),
HMGB1 (data not shown), IL-1b (p < 0.01) (ii), IL-8
(p < 0.05) (iv), and GM-CSF (p < 0.05) (v) but had no sig-
nificant effect on IL-6 (p = 0.44) (iii) and MMP3
(p = 0.91) (vi) compared to challenge with HK4616.
To answer the question of whether epithelial cells are a
potential source of IL-1a in vivo, we investigated the cel-
lular localization of IL-1a in lung tissue from patients with
BOS. Our data show that airway epithelial cells (Fig-
ure 4Fi) and alveolar epithelial cells (Figure 4Fii) express
IL-1a and therefore are a potential source of IL-1a
in vivo. In addition, other nonepithelial cells are also posi-
tive for IL-1a and therefore may contribute to the IL-1a
detected in BAL.
IL-1a released from P. aeruginosa infected epithelial
cells induces fibroblast activation in vitro
Conditioned media from unchallenged PLEC (media),
PLEC challenged with HK4616 for 12 h (HK4616), and
PLEC challenged with live 4616 for 12 h (4616) (n = 4)
was collected, filtered to remove all bacteria, and applied
to PLF (n = 4). After 24 h, the media was harvested to
investigate changes in protein secretion (Figure 5A). Con-
ditioned media from PLEC challenged with HK4616 had
little to no effect on IL-8 (i), GM-CSF (ii), and MMP3
(iii) secretion compared to conditioned media from
unchallenged PLEC. In contrast, conditioned media from
PLEC infected with live 4616 induced a significant
increase in secretion of all inflammatory markers com-
pared to conditioned media from PLEC challenged with
HK4616 (all p < 0.01).
Previous work from our laboratory has demonstrated that
PLF are induced to adopt a highly inflammatory phenotype
in response to treatment with recombinant IL-1a and IL-1b
but no effect is seen following treatment with recombi-
nant HMGB1 (17). Therefore, to investigate whether the
IL-1a or IL-1b released from P. aeruginosa infected PLEC
are involved in the activation of an inflammatory pheno-
type in PLF, we pre-incubated the conditioned media from
PLEC challenged with live 4616 with IL-1a (IL-1aNab) or
IL-1b (IL-1bNab) neutralizing antibody for 1 h before add-
ing to the PLF. In addition, PLF were pretreated with IL-
1Ra for 1 h before the conditioned media was added to
investigate a role for the IL-1 receptor in PLF activation.
For all markers, neutralization of IL-1a, but not IL-1b, in the
conditioned media or blocking the IL-1R on PLF signifi-
cantly reduced gene expression and protein secretion,
suggesting that IL-1a, signaling via IL-1R, is the critical
alarmin released from P. aeruginosa challenged epithelial
cells involved in driving an inflammatory phenotype in
fibroblasts (Figures 5B–D).
Figure 4: Pseudomonas aeruginosa promotes cell death and alarmin release in lung epithelial cells in vitro. (A) Primary lung
epithelial cells (PLEC) (n = 4) were challenged with P. aeruginosa (PA01) at 104 or 105 colony-forming units (cfu)/mL for up to 24 h
and IL-1a release was measured. (B) PLEC (n = 4) were challenged with P. aeruginosa (PA01) and n = 7 strains of P. aeruginosa iso-
lated from post–lung transplant patients at 105 cfu/mL for 12 h and IL-1a release was measured. PLEC (n = 4) were challenged with
P. aeruginosa (4616) at 105 cfu/mL for up to 48 h and cytotoxicity (release of lactate dehydrogenase) (C) and IL-1a release (D) quanti-
fied. (E) PLEC (n = 4) were challenged with heat-killed P. aeruginosa strain 4616 (HK4616), live P. aeruginosa strain 4616 at 105 cfu/
mL (4616) or media alone (media) for 12 h and the release/secretion of IL-1a (i), IL-1b (ii), IL-6 (iii), IL-8 (iv), GM-CSF (v), and MMP3
(vi) quantified. Data were analyzed using paired t-tests and presented as mean  standard error of the mean. *p < 0.05, **p < 0.01,
***p < 0.001. (F) Lung tissue from patients with BOS was stained with an anti-IL-1a antibody to identify potential cellular sources of
IL-1a in vivo. IL-1a protein is expressed in bronchial (i) and alveolar (ii) epithelium as well as other nonepithelial cell types. IgG1 control
showed no staining in the epithelium (iii). DAPI was used as a nuclear counterstain. These data confirm that injured epithelium may
be one of the potential sources of IL-1a in vivo. BOS, bronchiolitis obliterans syndrome; DAPI, 40,6-diamidino-2-phenylindole; GM-CSF,
granulocyte-macrophage colony-stimulating factor; MMP3, matrix metalloproteinase 3.
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Figure 5: IL-1a is the primary epithelial alarmin driving fibroblast activation in vitro. (A) Primary human lung fibroblasts (PLF,
n = 4) were incubated with media from untreated primary human lung epithelial cells (PLEC, n = 4) (media), media from PLEC chal-
lenged with heat-killed Pseudomonas aeruginosa strain 4616 (HK4616), and media from PLEC challenged with live P. aeruginosa strain
4616 at 105 colony-forming units/mL (4616). Protein secretion of IL-8 (i), GM-CSF (ii), and MMP3 (iii) was quantified. (B) To investigate
the role of IL-1a and IL-1b, the media from PLEC challenged with live P. aeruginosa strain 4616 was preincubated for 1 h with IL-1a
(4 lg/mL) or IL-1b (4 lg/mL)–neutralizing antibody. To investigate the role of the IL-1R, PLF were pretreated for 1 h with IL-1Ra
(500 ng/mL) prior to the addition of conditioned media from PLEC. Relative gene expression (i) and protein secretion (ii) of IL-8 (B),
GM-CSF (C), and MMP3 (D) were quantified. Data were analyzed using paired t-tests and presented as mean  standard error of the
mean (A, n = 16; B–E, n = 8). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. GM-CSF, granulocyte-macrophage colony-
stimulating factor; MMP3, matrix metalloproteinase 3.
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Dexamethasone partially inhibits IL-1a induced
inflammatory responses in fibroblasts in vitro
Next we determined whether therapeutic approaches
commonly used in lung transplant recipients, namely,
corticosteroids and macrolide antibiotics, would inhibit
the proinflammatory phenotype of PLF driven by IL-1a.
Pretreatment of fibroblasts with increasing doses of dex-
amethasone significantly decreased the IL-1a induced
secretion of IL-6 and IL-8 (Figures 6A and C). In contrast,
pretreatment of fibroblasts with increasing doses of azi-
thromycin had no significant effect on the secretion of
IL-6 and IL-8 (Figures 6B and D). Dexamethasone, but
not azithromycin, exhibited a similar inhibitory effect on
IL-8 secretion from PLF stimulated with conditioned
media from PLEC challenged with live P. aeruginosa
(4616) (Figures 6E and F).
Discussion
Our understanding of risk factors that contribute to the
development of CLAD, particularly BOS, has increased
over the last 10 years. In addition, the impact of azithro-
mycin therapy in improving and protecting lung function
in a proportion of patients developing CLAD has been
clearly shown (39,40). However, there remains a lack of
A B
C D
E F
Figure 6: Influence of dexamethasone and azithromycin on IL-1a induced IL-8 and IL-6 protein secretion by human lung
fibroblasts in vitro. Primary lung fibroblasts (PLF) were treated with the indicated concentrations of dexamethasone (A, C, and E) or
azithromycin (B, D, and F) for 1 or 24 h, respectively, after which IL-1a (100 pg/mL) (n = 3) or media from primary lung epithelial cells
(PLEC) challenged with live Pseudomonas aeruginosa strain 4616 (4616) (n = 6) was added and the cells were incubated for 24 h. To
investigate the role of IL-1a, the conditioned media from PLEC was pre-incubated for 1 h with IL-1a (4 lg/mL) neutralizing antibody.
Secretion of IL-6 (A and B) and IL-8 (C–F) was quantified. Data were analyzed using paired t-tests and presented as mean  standard
error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001.
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therapeutic options other than retransplantation for recipi-
ents with an azithromycin nonresponsive progressive
decline in lung function due to BOS.
The association between P. aeruginosa in the lung allo-
graft and an increased risk of BOS has been demon-
strated in numerous studies. A study by Gregson et al
showed that the likelihood of transition from transplant
to BOS was increased by the interaction between Pseu-
domonas and CXCL1 and that the risk of moving from
transplant to death was associated with Pseudomonas
infection (14). Dickson et al have demonstrated that
symptomatic transplant recipients have a higher preva-
lence of P. aeruginosa whereas asymptomatic transplant
recipients have a higher prevalence of P. fluorescens
(13). Our group and others have shown that de novo
acquisition of P. aeruginosa in recipients who were not
infected pretransplant is a risk factor for development of
BOS, whereas those re-infected after transplant, proba-
bly from an upper airway reservoir, did not have an
increased risk of BOS compared to those free of P.
aeruginosa (6,12). A study by Vos et al showed a similar
association between presence of P. aeruginosa in the
lung allograft but in contrast showed that this association
was strongest in recipients with cystic fibrosis (7).
Patients with cystic fibrosis are much more likely to be
infected with P. aeruginosa prior to transplant than other
groups. These conflicting results indicate that the mecha-
nisms by which this organism increases the risk of BOS
require evaluation.
In this study, we show that IL-1a, but not HMGB1, is
present in higher concentrations in BAL from lung trans-
plant recipients developing BOS than those who do not
develop BOS within 3 years of transplant. Furthermore,
we show that the IL-1a concentrations are highest within
3 months of BOS diagnosis and correlate with BAL IL-8
levels and neutrophilia. However, whether the elevation
in IL-1a around the time of BOS diagnosis is an impor-
tant factor contributing to disease pathology or is simply
a consequence of BOS development requires further
investigation. Additionally, IL-1a concentration was higher
in BAL samples with positive cultures for P. aeruginosa
compared to culture negative samples or samples posi-
tive for other organisms. A potential limitation to the
interpretation of our data is the lack of data regarding the
presence or absence of viruses in our patient cohort.
Future studies investigating the association between the
levels of IL-1a and viral infection in the development of
BOS would be of great interest. The lack of a difference
in HMGB1 levels in patients with BOS in our study is in
agreement with data from Saito et al, who also reported
no differences in HMGB1 although other alarmins such
as S100A8 were found to be elevated in patients with
BOS (41).
Epithelial injury has been recognized as a key event in
the pathogenesis of BOS in both animal models and
human histological studies (13,26,42,43). However, the
mechanism by which epithelial injury leads to chronic
inflammation and fibrotic remodeling in the small and
medium sized airways has not been elucidated. Specifi-
cally, the role of alarmins such as IL-1a in the develop-
ment of BOS has not been previously established. Our
study demonstrates that infection of airway epithelium
with P. aeruginosa causes cell injury and death and that
the alarmins released are sufficient to activate lung
fibroblasts to adopt a potent pro-inflammatory phenotype
in vitro. Furthermore, we show that IL-1a is the major
alarmin released from the damaged epithelial cells and
that it is the key factor responsible for the activation of
the inflammatory fibroblast phenotype in vitro.
Although our in vitro data demonstrate clearly the impor-
tance of IL-1a released from infected epithelial cells in
activating lung fibroblasts, it is possible that in the com-
plex milieu of the transplanted lung, other cells may act
as a source of IL-1a and that other alarmins may con-
tribute to fibroblast activation. For example, although our
in vitro model has the benefit of using primary airway
epithelial cells and primary lung fibroblasts as well as
clinically isolated Pseudomonas strains, it is limited by
the absence of immune cells or direct cell-to-cell contact.
Therefore, another potential mechanism inducing BOS
after transplantation or bacterial infection may be activa-
tion of the adaptive immune system by alarmins released
by damaged cells. IL-1 family members have previously
been shown to be involved in activation of Th1 and Th17
responses (44). Additionally, in a previous study, accumu-
lation of dendritic cells in the lung in response to cigar-
ette smoke was shown to be IL-1a dependent (45). The
relationship between innate and adaptive immunity has
been described in detail in several review articles (20,46–
48).
Safe and effective anti-inflammatory treatment strategies
for lung transplant patients are an important considera-
tion. Interestingly, our study demonstrated that inflam-
mation from lung fibroblasts induced by IL-1a could not
be reduced by azithromycin, which is commonly used to
treat BOS. It is estimated that azithromycin is effective
in approximately 50% of posttransplant patients who
develop BOS. Significantly, a recent study from our
group has demonstrated that lung transplant patients
with persistent airway neutrophilia despite azithromycin
treatment have significantly elevated levels of IL-1a in
their BAL compared to other phenotypes of CLAD includ-
ing azithromycin reversible allograft dysfunction (49). The
results described in the current study suggest that the
epithelial alarmin IL-1a may play an important role in con-
tributing to chronic inflammation and the development of
BOS in the transplanted lung. As IL-1a driven inflamma-
tory activation of fibroblasts could be partially reduced by
dexamethasone, anti-IL-1a compounds could be a poten-
tial anti-inflammatory therapy for transplant patients who
developed BOS that is unresponsive to azithromycin.
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Figure S1: Neutrophil numbers are elevated at the
time of BOS diagnosis. (A) Mean IL-1a (i) and HMGB1
(iv) concentration and neutrophil percentage (ii) and num-
ber (iii) in BAL of lung transplant recipients who develop
BOS within 3 years of transplant (n = 25). BAL were
grouped into BAL samples taken >3 months before or
after BOS diagnosis (>3 months before BOS) and BAL
samples taken <3 months before or after BOS diagnosis
(<3 months before BOS). Matching patient samples are
shown with a connecting line. Mean HMGB1 (B) concen-
trations and neutrophil number (C) in BAL of lung trans-
plant recipients who remained stable at 3 years (n = 25) or
develop BOS within 3 years of transplant (n = 25). BAL
from patients who developed BOS were grouped into BAL
samples taken >3 months before or after BOS diagnosis
and BAL samples taken <3 months before or after BOS
diagnosis. Data were analyzed using Mann–Whitney U
test or paired t-tests as appropriate and are presented as
median. Correlation between the relative time from BOS
diagnosis and HMGB1 (D) concentration and neutrophil
number (E) in BAL samples from patients who develop
BOS. Data were analyzed using a multiple linear regres-
sion model with varying intercept. All p-values relate to the
gradient of the fitted line. To plot an average line, we took
the mean value at T0 (time of BOS diagnosis) as the y-
intercept. **p < 0.01, ***p < 0.001, ****p < 0.0001.
BAL, bronchoalveolar lavage; BOS, bronchiolitis obliterans
syndrome; HMGB1, high mobility group protein B1.
Figure S2: Increased neutrophilia, but not HMGB1, in
BAL of culture positive posttransplant patients who
develop BOS. Mean HMGB1 (A) concentration and neu-
trophil number (B) in BAL from culture positive (any
organism) and culture negative (no organisms) patients
who developed BOS (BOS) (n = 25) or remained stable
(non-BOS) (n = 25). Mean neutrophil number in culture
negative (no organisms), culture positive for any organ-
ism other than Pseudomonas aeruginosa (other
organisms), and culture positive for P. aeruginosa (P.
aeruginosa) BAL samples from patients who remained
stable (non-BOS) (C) and patients who developed BOS
(D). Data were analyzed using Mann–Whitney U test and
are presented as median. *p < 0.05, **p < 0.01,
***p < 0.001. BAL, bronchoalveolar lavage; BOS, bron-
chiolitis obliterans syndrome; HMGB1, high mobility
group protein B1.
Figure S3: Elevated neutrophilia in culture positive
lung transplant recipients around the time of BOS
diagnosis. Correlation between the relative time from
BOS diagnosis and HMGB-1 (A) concentration and neu-
trophil percentage (B) and number in (C) culture negative
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(i) and culture positive (ii) BAL samples. Data were ana-
lyzed using a multiple linear regression model with vary-
ing intercept. All p-values relate to the gradient of the
fitted line. To plot an average line, we took the mean
value at T0 (time of BOS diagnosis) as the y-intercept.
BOS, bronchiolitis obliterans syndrome.
Figure S4: No correlation between IL-1a levels and
time from transplant. Correlation between the number
of months after transplantation and IL-1a (A) and HMGB1
(B) concentrations and neutrophil percentage (C) and
number (D) in BAL samples from non-BOS patients. Data
were analyzed using a multiple linear regression model
with varying intercept. All p-values relate to the gradient
of the fitted line. To plot an average line, we took the
mean value at T6 (time of transplant was taken as T0) as
the y-intercept. BAL, bronchoalveolar lavage; BOS, bron-
chiolitis obliterans syndrome; HMGB1, high mobility
group protein B1.
Figure S5: IL-1a is elevated in BOS patients with
more than one culture positive BAL sample. Non-BOS
and BOS patients were divided into those with no posi-
tive BAL cultures, those with one positive BAL culture,
and those with more than one positive BAL culture, and
the levels of IL-1a (A and B) and HMGB1 (E and F) and
the percentage of neutrophils (C and D) assessed. Data
were analyzed using Mann–Whitney U test and are pre-
sented as median. *p < 0.05. BAL, bronchoalveolar
lavage; BOS, bronchiolitis obliterans syndrome; HMGB1,
high mobility group protein B1.
Table S1: Primer sequences. Forward and reverse
sequences for all primers used in this study.
Table S2: BAL organism data. Percentage and number
of BAL with organisms cultured. Differences between
the BOS and non-BOS patient groups were analyzed
using chi-square test for trend test. BAL, bronchoalveolar
lavage; BOS, bronchiolitis obliterans syndrome.
Table S3: Patients with multiple organisms. Number of
BAL samples positive for more than one organism and
the combination of organisms. Differences between the
BOS and non-BOS patient groups were analyzed using
chi-square test for trend test. BAL, bronchoalveolar
lavage; BOS, bronchiolitis obliterans syndrome.
Table S4: Time of colonization. Number of positive BAL
samples relative to time from transplant or time from
BOS diagnosis. BAL, bronchoalveolar lavage; BOS, bron-
chiolitis obliterans syndrome.
Data S1: Supplementary Materials and Methods.
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